Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
Cao JX., You J., Wu LH., Luo K., Wang ZX.
Systematic Review with a reported sample of 19, published in World J Clin Cases (2022) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Systematic Review
- Journal
- World J Clin Cases (2022)
- Reported sample size
- 19
- Source database
- Europe PMC
- PMID
- 36186213
- PMCID
- PMC9516915
- DOI
- 10.12998/wjcc.v10.i27.9714
- Citations
- 4
Abstract (original English)
Background Currently, ongoing trials of mesenchymal stem cells (MSC) therapies for coronavirus disease 2019 (COVID-19) have been reported. Aim In this study, we investigated whether MSCs have therapeutic efficacy in novel COVID-19 patients. Methods Search terms included stem cell, MSC, umbilical cord blood, novel coronavirus, severe acute respiratory syndrome coronavirus-2 and COVID-19, applied to PubMed, the Cochrane Controlled Trials Register, EMBASE and Web of Science. Results A total of 13 eligible clinical trials met our inclusion criteria with a total of 548 patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels after stem cell therapy ( P = 0.11). A reduction of D-dimer levels was also not observed in patients after stem cell administration ( P = 0.82). Furthermore, interleukin 6 (IL-6) demonstrated no decrease after stem cell therapy ( P = 0.45). Finally, we investigated the overall survival (OS) rate after stem cell therapy in COVID-19 patients. There was a significant improvement in OS after stem cell therapy; the OS of enrolled patients who received stem cell therapy was 90.3%, whereas that of the control group was 79.8% ( P = 0.02). Conclusion Overall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.